

2021 高雄國際癌症研討會 議程表
2021 Kaohsiung International Cancer Symposium

| 7 月 17 日(星期六) Saturday, 17 July | | | |
|---------------------------------|--|------------------------|--|
| Breast Cancer | | | |
| Time | Topic | Speaker | Moderator |
| 08:20-08:30 | 貴賓致詞 | | |
| 08:30-09:00 | Marker-guided Target therapy and Immuno-therapy | Mien-Chie Hung 洪明奇 | Ming-Feng Hou 侯明鋒 |
| 09:00-09:30 | Themis2 enhances cancer stemness and chemoresistance via suppressing p-Met/PTP1B interaction to activate Met | Lu-Hai Wang 王陸海 | Mien-Chie Hung 洪明奇 |
| 09:30-10:00 | One-Step Formulation of mPEGylated Liposome by Anti-mPEG Bispecific Antibodies for Cancer Targeted Therapy | Tain-Lu Cheng 鄭添祿 | Lu-Hai Wang 王陸海 |
| 10:00-10:30 | Know Thy Neighbour: Dissecting Intra-tumour Heterogeneity | Ruby Huang 黃韻如 | King-Jen Chang 張金堅 Yi-Chia Wu 吳益嘉 |
| 10:30-10:50 | Coffee Break | | |
| 10:50-11:20 | Single Cell Derived Organoid Toward Precision Medicine | Ying Chih Chang 張瑛芝 | Ling-Ming Tseng 曾令民 |
| 11:20-11:50 | Gut microbiota and Gastrointestinal cancer | Deng-Chyang Wu 吳登強 | Shin-Cheh Chen 陳訓徹 |
| 11:50-12:20 | Gut microbiota in premenopausal breast cancer: should we pay attention? | Chih-Po Chiang 江誌博 | Jyh-Cherng Yu 俞志誠 Ming-Shen DAI 戴明榮主任 |
| 12:30-13:30 | Lunch | | |
| 13:30-14:00 | Bring biosimilars to life: experience to embed trastuzumab biosimilar into clinical practice | Marc Thill | Chiun-Sheng Huang 黃俊升 |
| 14:00-14:30 | Balancing efficacy, toxicity and QoL in treatment with cancer immunotherapy | Wei-Pang Chung 鍾為邦 | Shyr-Ming Sheen-Chen 沈陳石銘 |
| 14:30-15:00 | New Developments in chemotherapy-based treatment for early breast cancer | Chin-Yao Lin 林金瑤 | Tsui-Fen Cheng 鄭翠芬 Yao-Lung Kuo 郭耀隆 |
| 15:00-15:30 | Exploring biomarkers of chemotherapy outcome in MBC treatment | Chan-Keng Yang 楊展庚 | Yen-Shen Lu 盧彥伸教授 Hsien-Kun Chang 張獻崑 |
| 15:30-15:50 | Coffee Break | | |

| | | | |
|--------------------|--|-------------------------|--|
| 15:50-16:20 | Tailored HER2-positive Early Breast Cancer Treatment Efficacy based on Neoadj Outcome | Hung-Wen Lai 賴鴻文 | Dar-Ren Chen 陳達人 Shou Tung Chen 陳守棟 |
| 16:20-16:50 | Transforming 1st line treatment for HR+Her2- pre- menopausal MBC | Liang-Chih Liu 劉良智 | Dah-Cherng Yeh 葉大成 |
| 16:50-17:20 | New Era of Endocrine Treatment with OS Benefit in HR+ HER2- Advanced Breast Cancer | Chieh-Han Chuang 莊捷翰 | Ming-Yang Wang 王明暘 |
| 17:20-17:50 | A new era of extended adjuvant treatment -optimize efficacy in right patients | Wen-Ling Kuo 郭玟伶 | Fang-Ming Chen 陳芳銘 |
| 17:50-18:00 | Panel Discussion & Closing | | |

7月18日(星期日) Sunday, 18 July

Auditorium II

Breast Cancer

| Time | Topic | Speaker | Moderator |
|-------------|---|-------------------------|--------------------------|
| 08:30-09:00 | Study on Awareness of Financial Burden of Breast Cancer Treatment in Japan | Shinji Ohno 大野真司 | Hong-Tai Chang 張宏泰 |
| 09:00-09:30 | Can you use carboplatin for breast cancer? | Takashi Ishikawa 石川孝 | Chao-Ming Hung 洪朝明 |
| 09:30-10:00 | Establishment of PRO collecting platform using LINE-ePRO and its application to breast cancer patients | Tetsu Hayashida 林田哲 | Kun-Ming Rau 饒坤銘 |
| 10:00-10:20 | Coffee Break | | |
| 10:20-10:50 | CDK4/6 Inhibitors in Breast Cancer: The Value of Treatment in Rb-Proficient Triple-Negative Breast Cancer | Mei-Ren Pan 潘美仁 | Chen-Hsiang Chang 張振祥 |
| 10:50-11:20 | Efficacy of cytokine-induced killer (CIK) cells in combination with FAK inhibitor for triple-negative breast cancer | Chi-Wen Luo 羅啟文 | Kuo-Ting Lee 李國鼎 |
| 11:20-11:50 | Overall survival with palbociclib + fulvestrant in women with HR+, HER2- advanced breast cancer: Updated analyses from PALOMA-3 | Charles Hsiao 蕭君平 | Fu Ou-Yang 歐陽賦 |
| 11:50-12:20 | Targeted Breast and Axillary Lymph Node Surgery with Intraoperative Radiotherapy for Breast Cancer | Li-Jyun Gao 高理鈞 | Fang-Ming Chen 陳芳銘 |
| 12:20-12:30 | Closing | Fang-Ming Chen 陳芳銘 | |